Antibody-drug conjugates( ADCs) are agrowing class of therapeutics that harness the specificity of antibodies and the cellkilling potency of small-molecule drugs.B eyond cytotoxics, there are few examples of the application of an ADC approach to difficult drug discovery targets. Here, we presentt he initial development of an on-internalising ADC, with av iew to selectively inhibiting an extracellular protein. Employing the wellinvestigated matrixm etalloproteinase-9 (MMP-9) as our model, we adapted ab road-spectrum, nonselective MMP inhibitor for conjugation and linked this to aM MP-9-targeting antibody. The resulting ADC fully inhibitsM MP-9, and ELISA resultss uggest antibody targeting can direct an onselectivei nhibitor.
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Currentc linical antibody-drug conjugates (ADCs) combine the high specificity and long circulating half-life of an antibody with the cell-killingp otency of as mall-molecule payload to generate at argeted chemotherapeutic. [1] Designed to improve the therapeutici ndex of cytotoxic agents, two distinct mechanistic classes of payload have mosto ften been conjugated to monoclonala ntibodies;m icrotubule inhibitors (e.g.,m aytansines, auristatins)a nd DNA-modifying agents( e.g.,c alcheamicins, PBD dimers, duocarmycins). [2] [3] [4] [5] [6] Currently,t here are four ADCs on the market ando ver 65 in clinical evaluation;h owever,t here are limited examples of ADCs employing non-cytotoxic small molecules. [7] [8] [9] [10] [11] [12] [13] [14] As part of ag rowing interest in the field of targeted delivery of smallm olecules, we began to explore an ovel application of the ADC approach to the selective inhibition of an extracellular protein. Using matrix metalloproteinase-9 (MMP-9, also knowna sg elatinase B) as our model, we conjugated ab road-spectrum MMP inhibitor to as elective MMP-9 antibody.
MMPs are af amily of structurally relatedz inc-binding proteolytice nzymes. [15] Individual MMPs are promising drug targets;m any diseases, including cancer, inflammation, and vascular disease, are associated with altered MMP expression and aberrant proteolysis. [16] [17] [18] [19] Significant drug discovery effort has been invested into generating small-moleculeM MP inhibitors that target the active-site zinc in the catalytic domain. Despite the investigation of more than 50 of these inhibitors in clinical trials, efforts with first-generation compounds were hampered either by dose-limiting toxicity or insufficient clinical benefit. [20] One explanation for this failure is the high degree of sequence and structurals imilarity in the catalytic domain of MMPs, which results in broad-spectrum, nonspecific inhibitors, althoughm ore selective next-generation compoundsa re now beginning to appear. [18] Monoclonal antibodies selectivef or specific MMPs have been successfully generated. [21] However, as these targeting antibodies interact with surfacel oops rather than the active site, they often lack sufficient functional potency.
We describe herein anew approach towards the selective inhibition of MMPs, specifically MMP-9, through combining the specificity and high affinity of an antibody with the potency of as mall-molecule inhibitor.M MP-9 shows particular promise as at herapeutic target, having been associatedw ith an umber of pathological processest hat contributet ot umorigenesis, metastasis and chronic inflammation. [22, 23] As ar esult,M MP-9 is perhaps the best investigated of the MMPs and thus provides a valuablem odel to begin exploring the application of an ADC to retarget anonselective inhibitor.
To investigate our ADC approach, we neededt oa dapt a broad-spectrum MMP inhibitor for conjugation. Many MMP inhibitors are hydroxamateb ased;t he hydroxamic acid motif coordinates the active-site zinc ion in ab identate fashion to generate inhibitors with high affinity but poor MMP selectivity. [24] One such inhibitor is CGS27023A ( Figure 1A ), which was originally discovered as an orally active MMP-3 inhibitor. It was soon demonstratedt ob eapotent inhibitor of many MMP family members, including MMPs 9a nd 2. [25, 26] The crystal structure of CGS27023A in complex with the MMP-12 catalytic domain has been successfully resolved. [26] This reveals the pyridine ring of the inhibitor to be relativelys olvent exposed, thus potentially providing as ite for linker derivatisation. In fact, there is literature precedent for the PEGylation of CGS27023A through ab enzyld erivative. [27] Consequently,w eo pted to design and synthesise CGS27023A-linker derivatives for conjugation to am onoclonal antibody.
To install al inker forc onjugation,w ereplaced the pyridine ring of CGS27023A with an aniline, exploring both the 3-and 4-positions initially to determine if there was an impact on in-hibitor potency(Schemes S1 and S2 in the Supporting Information). Both anilines were subsequently coupled to maleimide hexanoica cid to provideahandle for cysteinec onjugation, thus generating linker derivatives 1 and 2 ( Figure 1A ). CGS27023A and linker compounds 1 and 2 were tested in a fluorometric biochemical assay against MMP-9b yu sing the SensoLyte 520 MMP-9 assay kit (AnaSpec). This indicated no loss in potency at MMP-9( Figure 1B) . Furthermore, 1 and 2 displayed potent inhibition of the most closely relatedp rotease, MMP-2( also knowna sg elatinase A), thereby confirming that the broad-spectrumb ehaviour of this compound was maintained ( Figure S1 ). We chose to move forwardw ith CGS27023A derivative 2 as more material was available.
In addition to adapting ab road-spectrum inhibitor for conjugation, we required an antibody that specifically binds to MMP-9 with high affinity.I deally this antibody would target an epitopen eart o, butd istinct from, the zinc-binding site, thereby leaving the site free for occupation by as mall-molecule inhibitor.One of the earliest anti-MMP-9 antibodies reported was REGA-3G12,amousem onoclonal generatedb yh ybridoma technology against the human MMP-9 catalytic domain. [28] This antibodyi sr eported to be highly selectivef or MMP-9 and to recognise Trp116-Lys214, ar egion of the catalytic domain separate from the zinc-binding site. [29] This suggested that REGA-3G12 might be suitable for selective delivery of as mall-molecule inhibitor to MMP-9.
In view of our intention to conjugateR EGA-3G12 to as mall molecule through its interchaind isulfides, we generated the antibodyi nc himeric IgG1 format, thus providing am aximum of eight sites for conjugation as opposed to the ten found in mouse IgG1. Transient expression of REGA-3G12 in Expi293F cells and purification by protein Aa nd size-exclusion chromatography resultedi nafinal yield of 51 mg L
À1
.A nalysis of the antibody by SDS-PAGE demonstrated it to be pure (> 95 %), and high-resolution Orbitrap masss pectrometry enabled sequencem atching to the observed molecular weight( Figure  S2 ). Next, it was imperative to determine the affinity of REGA-3G12 for MMP-9, as the principle of our retargeting ADC approach relies upon strong antibody bindingd riving selectivity.
We measured the affinity (K D )o fR EGA-3G12 for the human MMP-9 catalytic domain by using biolayer interferometry (BLI). Briefly,t he antibodyw as captured on protein Gs ensors,a nd its bindingt oh uman catalytic MMP-9 was analysed by using a twofold dilution series with at op concentration of 12.5 nm. REGA-3G12 was found to have very high affinity (K D = 97.4 pm), displaying the ideal antibody-binding kinetics of af ast on-rate and slow off-rate (Figures 2A and S3) . To confirm the selectivity of REGA-3G12, we tested binding to MMP-2, which shares7 8% sequence identity in the catalytic domain. Pleasingly,n ob inding to MMP-2 was observed by BLI or ELISA (Figures 2B and  S4) .
Having confirmed the binding selectivity of REGA-3G12 for MMP-9, it was next tested for activity in the fluorometric assay. Despite the high affinity of REGA-3G12,i td isplayed very weak inhibition of MMP-9activity( Figure 2C ). Consequently,potency changes after small-molecule inhibitor conjugation could be readilyo bserved.
Prior to generating antibody-drug conjugates, we confirmed whether the CGS27023A payloadc ould inhibit MMP-9i nt he presence of REGA-3G12. We compared the inhibition of MMP-9 by REGA-3G12,s mall molecule 2 and am ixed sample mimicking an ADC with ad rug-to-antibody ratio (DAR) of 4( Figure 3 ). In the fluorometric assay,R EGA-3G12 aloneb ehaved as a weak,p artial inhibitor of MMP-9, as observed previously.W hen Having successfully demonstrated the simultaneous binding of antibody and smallm olecule, we constructed the ADC. For conjugation,R EGA-3G12 was immobilised on protein Ab eads and reduced with the mild reducing agent tris(2-carboxyethyl)-phosphine hydrochloride (TCEP). Followings imultaneous removal of TCEP and buffer exchange to give conditions suitable for maintaining the reduced antibody (PBS, 5mm EDTA, pH 7.4), 4.4 or 8.8 equivalentso f2 were added to yield conjugates of average DARs of 4a nd 8, respectively,a sd etermined by LCMS (Figures S5 and S6 ). Solid-phase conjugation was found to be necessary to completelyr emove all of the potent, unconjugated small molecule by using repeated PBS + 10 % DMA washes. Alternative purification methodsu sually employed after solution-phase conjugation (e.g.,g el filtration, ultracentrifugation) were found to be inadequate. Thec onjugates were subsequently tested by ELISA,w hich confirmed that binding of the antibody was maintained after conjugation ( Figure S7) .
Next, we examined the activity of the ADCs in the fluorometric assay.B oth DAR = 4a nd DAR = 8A DCs fully inhibited MMP-9w ith an acceptable level of potency,a nd no significant change in potencyw as observed upon increasing the DAR from 4t o8( IC 50 = 22 AE 6.5 and 15.7 AE 9.8 nm,r espectively; Figure3). This result provided excellent promise for our ADC approach, demonstrating that both antibody and small molecule could maintain binding to MMP-9 as part of an ADC.
This ADCa pproacht os electivei nhibitioni sd riven by the theoryt hat superior antibody-binding kinetics would drive selectivity.T oe xamine this, we developeda nE LISA to indicate whetherA DC binding is driven by the antibody or the small molecule. For this, two ADCs were compared;R EGA-3G12 and an isotypecontrol hIgG1, both conjugatedt o2.
First, 384-well plates were coated with human catalytic MMP-9 or the closely related human MMP-2, and conjugates of eitherR EGA-3G12o rn onbinding isotype control were added. Subsequentw ash-off and incubation with anti-humanF c horseradish peroxidase would therefore only lead to as ignal if either ADC was still present,t hus demonstrating whether the broad-spectrum small-molecule inhibitor alone could drive binding of an ADC at either MMP-9 or MMP-2. At MMP-9, binding curves were observed only for REGA-3G12 alone and its conjugate with 2 ( Figure 4A ). However,nosignal wasobserved for the isotypec ontrol ADC. Furthermore, at MMP-2n or ead out was observed for either ADC. This result suggests that antibody-binding kinetics could drive ADCs electivity,a sn ob inding of our REGA-3G12 ADC was observeda tM MP-2 (Figure 4B) . Following this result, we endeavoured to compare the impact of conjugation on the bindinga ffinity of compound 2 at MMP-9a nd -2 by using surface plasmon resonance (SPR). Unfortunately,t hesee fforts were withouts uccess. We were unable to determine the binding affinity of compound 2,a nd, to the best of our knowledge,n ob inding affinity for CGS27023A is reportedi nt he literature, neither are conditions for SPR analysis of inhibitors at MMP-9 or -2.
In summary,w ehave presented the first example of an ADC targeting an extracellular protein in which both the antibody and small molecule bind to the same target, with the aim of imparting selectivity to an onselective, broad-spectrum inhibitor.T his ADC was designed forM MP-9, an attractive therapeutic target for which the progress of small-molecule inhibitors has previously been hampered by lack of selectivity.T he anti-MMP-9 antibody REGA-3G12 was identifieda nd successfully demonstrated to fit the binding selectivity and kinetics requirements for our ADC model.T he nonselective MMP inhibitor CGS27023A was effectively adapted for cysteinec onjugation to an antibody with maintained potency at MMP-9 and the closely related MMP-2.T he resulting ADC displayed potent inhibition of MMP-9, and we successfully developed an ELISA that encouragingly suggested that selectivity for MMP-9 over MMP-2 in vitro is possible. This also validated the hypothesis that as uitable antibody can drive the binding of an ADC and provide ab asis for retargeting an onselective small-molecule inhibitor.T his early work therefore suggestst hat such an ADC approachc ould provide as electivity solutionf or difficult drugdiscoveryt argets. We shall report on the further development of this ADC approachtoa dditional targets in due course.
Experimental Section
Details of all synthetic procedures, characterisation data for new compounds, protein expression and characterisation, conjugation and assay protocols are given in the Supporting Information.
